Blacklisting Icahn: How Some Drug Companies Keep Out Activists

  • Pharmaceutical firms bar resale of stakes to activist managers
  • 'I've never heard of such a thing,' activist Griggs says

When Concordia Healthcare Corp. agreed to issue a 14 percent stake to a private equity firm, the Canadian drug manufacturer tucked into the deal several layers of protection from shareholder activists.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.